Last Updated : October 16, 2023
Details
Generic Name:
omalizumab
Project Status:
Not filed
Therapeutic Area:
Chronic rhinosinusitis with nasal polyps
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Xolair
Project Line:
Reimbursement Review
Project Number:
N/A
Manufacturer Requested Reimbursement Criteria1:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Submission Type:
Non Submission
Indications:
As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps inadequately controlled by intranasal corticosteroids alone.
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : October 16, 2023